The future of colon cancer prevention

Annals of the New York Academy of Sciences

Volumn 952, Issue , 2001, Pages 88-108

  Umar, Asad ^a   Viner, Jaye L ^a   Hawk, Ernest T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aberrant crypt foci; Adenomas; Carcinoma; Celecoxib; Colonoscopy; Colorectal cancer (CRC) prevention; COX 1 2; Cyclooxygenase; Difluoromethylornithine (DFMO); Dysplasia; High resolution chromoendoscopy; Hyperplasia; Microarray expression profiling; Nonsteroidal anti inflammatory drugs (NSAID); Optical coherence tomography; Optical reflectance spectroscopy; Proteomics; Sigmoidoscopy

Indexed keywords

CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FOLIC ACID; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; PELITINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D;

CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CANCER; CONFERENCE PAPER; DRUG MECHANISM; EARLY DIAGNOSIS; GENE TECHNOLOGY; HUMAN; MOLECULAR BIOLOGY; VALIDATION PROCESS;

EID: 0035680424     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb02730.x     Document Type: Conference Paper

References (138)

1. Cancer statistics, 2001
2. Colonic adenomas: Prevalence and incidence rates, growth rates, and miss rates at colonoscopy
3. The effect of fecal occult-blood screening on the incidence of colorectal cancer
4. Prevention of colorectal cancer by colonoscopic polypectomy
5. The onset and extent of genomic instability in sporadic colorectal tumor progression
6. Errors in DNA replication as a basis of malignant changes
7. A mutator phenotype in cancer
8. Genetic alterations during colorectal tumor development
9. Cancer-susceptibility genes. Gatekeepers and caretakers
10. A genetic model for colorectal tumorigenesis
11. Lessons from hereditary colorectal cancer
12. Genetic pathways in colorectal and other cancers
13. Molecular changes in the ki-ras and apc genes in colorectal adenomas and carcinomas arising in the same patient
14. Molecular interactions in the Vogelstein model of colorectal carcinoma
15. The role of the e-cadherin/catenin complex in gastrointestinal cancer
16. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps
17. Prospective study of the frequency and size distribution of polyps missed by colonoscopy
18. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies
19. Flexible sigmoidoscopy
20. Aberrant crypt foci of the colon as precursors of adenoma and cancer
21. High-resolution chromoendoscopy for the diagnosis of diminutive colon polyps: Implications for colon cancer screening
22. Colonic polyp differentiation using time-resolved autofluorescence spectroscopy
23. Ex vivo optical properties of human colon tissue
24. Detection of preinvasive cancer cells
25. Optical coherence tomography
26. In vivo endoscopic optical biopsy with optical coherence tomography
27. High resolution imaging of the upper respiratory tract with optical coherence tomography: A feasibility study
28. New technology for high-speed and high-resolution optical coherence tomography
29. Ultrahigh-resolution ophthalmic optical coherence tomography
30. Scanning single-mode fiber optic catheter-endoscope for optical coherence tomography
31. High resolution in vivo intra-arterial imaging with optical coherence tomography
32. In vivo endoscopic OCT imaging of precancer and cancer states of human mucosa
33. Endoscopic applications of optical coherent tomography
34. Laser capture microdissection
35. Quantitative amplification of genomic DNA from histological tissue sections after staining with nuclear dyes and laser capture microdissection
36. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia
37. Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection
38. Molecular profiling of clinical tissues specimens: Feasibility and applications
39. Molecular profiling of human cancer
40. Exploring the new world of the genome with DNA microarrays
41. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
42. Timely toxicology
43. Validation of tissue microarray technology in breast carcinoma
44. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays
45. Proteomics: A new approach to the study of disease
46. Clinical outcomes in statin treatment trials: A meta-analysis
47. Reducing cardiovascular morbidity and mortality in the elderly
48. Natural history of untreated colonic polyps
49. Colorectal cancer screening: Clinical guidelines and rationale
50. American cancer society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers
51. Colorectal cancer prevention 2000: Screening recommendations of the American College of Gastroenterology
52. Family history of cancer and colon cancer risk: The Utah population database
53. Risk of colorectal cancer in the families of patients with adenomatous polyps
54. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
55. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer
56. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel
57. The best screening test for colorectal cancer - A personal choice
58. Approaches to prevention of epithelial cancer during the preneoplastic period
59. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
60. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
61. The role of cyclooxygenases in inflammation, cancer, and development
62. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
63. Cyclooxygenase-2 expression is related toprostaglandin biosynthesis and angiogenesis in human gastric cancer
64. Expression of cyclooxygenase-2 (cox-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a cox-2 inhibitor, ns-398
65. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
66. Cyclooxygenase-2 expression in human esophageal carcinoma
67. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer
68. Cox-2 expression is induced by uvb exposure in human skin: Implications for the development of skin cancer
69. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
70. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder
71. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
72. Suppression of intestinal polyposis in apc delta716 knockout mice by inhibition of cyclooxygenase 2 (cox-2)
73. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
74. Modulation of apoptosis and bcl-2 expression by prostaglandin e2 in human colon cancer cells
75. Alteration of tumor growth by aspirin and indomethacin: Studies with two transplantable tumors in mouse
76. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors
77. Sulindac for polyposis of the colon
78. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
79. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas
80. Low incidence of colorectal cancer in patients with rheumatoid arthritis
81. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: Effects of dosage and timing
82. Colon cancer: A role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs
83. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti inflammatory drugs
84. Aspirin use and reduced risk of fatal colon cancer
85. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
86. Aspirin and the risk of colorectal cancer in women
87. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
88. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
89. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
90. Chemoprevention of intestinal polyposis in the apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
91. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
92. Ornithine decarboxylase as a target for chemoprevention
93. Ornithine decarboxylase activity in the rat and human colon
94. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa
95. Ornithine decarboxylase and polyamines in familial adenomatous polyposis
96. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma
97. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer
98. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine
99. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine
100. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps
101. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention
102. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer
103. Reduced growth rate of dimethylhydrazine-induced colon tumors in rats
104. Effects of cyclosporine and alpha-difluoromethylornithine on the growth of mouse colon cancer in vitro
105. Selenium and difluoromethylornithine additively inhibit dmh-induced distal colon tumor formation in rats fed a fiber-free diet
106. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice
107. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of APC mutant min mouse adenomas, and selective toxicity against apc mutant embryos
108. Combinatorial chemoprevention of intestinal neoplasia
109. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil
110. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with d,1-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet
111. Chemoprevention of colon carcinogenesis bydietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination
112. Differential sensitivity of pancreatic and colon cancer to cyclosporine and alpha-difluoromethylornithine in vivo
113. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin e2 levels in rat colon
114. Influence of k-ras activation on the survival responses of caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine
115. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer
116. Reducing mortality from colorectal cancerby screening for fecal occult blood. Minnesota colon cancer control study
117. Screening sigmoidoscopy and colorectal cancer mortality
118. Colorectal cancer and nonsteroidal anti-inflammatory drugs
119. Apoptosis and APC in colorectal tumorigenesis
120. Chemoprevention of colorectal cancer
121. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
122. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), gw7845, inhibits rat mammary carcinogenesis
123. Development of difluoromethylornithine (DFMO) as a chemoprevention agent
124. Folate, methionine, and alcohol intake and risk of colorectal adenoma
125. Folate and carcinogenesis: An integrated scheme
126. Calcium and the prevention of colon cancer
127. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue eb1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy
128. Prebiotics and probiotics: Are they functional foods?
129. Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth
130. Perillyl alcohol: Applications in oncology
131. Pre-clinical development of farnesyltransferase inhibitors
132. Tyrosine kinase inhibitors - Solid cancers
133. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
134. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the fit-1 vascular endothelial growth factor receptor
135. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
136. Promising new developments in cancer chemotherapy
137. Intravenous administration of onyx-015, a selectively replicating adenovirus, induces antitumoral efficacy
138. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma